Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.50 |
| ▸ | PGR | P06401 | 6/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17084888 | 0.90 | PDK2 (0.43) | PDK2PDK4PGRCYP26A1CYP3A4 | |
| SCHEMBL10758620 | 0.82 | PDK2 (0.50) | PDK2PDK4PGRLMNAELANE | |
| SCHEMBL461770 | 0.81 | LMNA (0.47) | PDK2PDK4PGRCYP3A4LMNA | |
| SCHEMBL29392540 | 0.81 | HTR2A (0.48) | PDK2PDK4PGRLMNAHTR2A | |
| SCHEMBL1627657 | 0.81 | HTR2A (0.48) | PDK2PDK4PGRLMNAHTR2A | |
| Ammonia Solution, Strong SCHEMBL11465690 | 0.78 | HTR2A (0.46) | PDK2PDK4PGRLMNAHTR2A | |
| SCHEMBL22973341 | 0.76 | PDK2 (0.36) | PDK2PDK4CYP3A4PDK1PDK3 | |
| SCHEMBL19204408 | 0.75 | CHRM2 (0.53) | PDK2PDK4CYP3A4LMNAHTT | |
| SCHEMBL31001030 | 0.74 | PDK2 (0.43) | PDK2PDK4PGRCYP3A4LMNA | |
| SCHEMBL29085489 | 0.73 | HTR2A (0.43) | PDK2PDK4PGRLMNAHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872590-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2018-11-14 | — | — | EP | disclosed |
| US-9837622-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| US-9837622-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| US-20150263297-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150263297-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| EP-2137179-B1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014008982-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2014-01-16 | — | — | WO | disclosed |
| EP-2586778-A2 | Pyridazinone derivatives useful as glucan synthase inhibitors | Merck Sharp & Dohme Corp. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-5055622-A | For treating neoplasms and dermatoses | HOFFMANN-LA ROCHE INC. (US) | 1991-10-08 | — | — | US | disclosed |
| US-5030764-A | Antitumor agents; treatment of skin disorders | HOFFMANN-LA ROCHE INC. (US) | 1991-07-09 | — | — | US | disclosed |
| US-5030765-A | Skin disorders, anititumor agents | HOFFMANN-LA ROCHE INC. (US) | 1991-07-09 | — | — | US | disclosed |
| US-5001276-A | Novel tetrahydronaphthalene and indane derivatives | HOFFMANN-LA ROCHE INC. (US) | 1991-03-19 | — | — | US | disclosed |
| US-4990703-A | Novel tetrahydronaphthalene and indane derivatives | HOFFMANN-LA ROCHE INC. (US) | 1991-02-05 | — | — | US | disclosed |
| US-4935560-A | ANTITUMOR AGENTS; SKIN DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1990-06-19 | — | — | US | disclosed |
| US-4870219-A | NEOPLASMS, DERMATOSES | HOFFMANN-LA ROCHE INC. (US) | 1989-09-26 | — | — | US | disclosed |
| US-4599347-A | ANTIULCER AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1986-07-08 | — | — | US | disclosed |
| US-4554280-A | ANTISECRETORY AGENTS, ANTIULCER AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-11-19 | — | — | US | disclosed |
| US-4435406-A | 2-PYRIDYL DERIVATIVES OF 1,3-DIOXOLO(4,5-F)BENZIMIDAZOLE RING COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150263297-A1 | Metal Complexes | SOD1, AP1M1, AP3M1 | PDK2 2330/4885PDK4 2670/4885PGR 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.